JP2016520520A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520520A5
JP2016520520A5 JP2016502189A JP2016502189A JP2016520520A5 JP 2016520520 A5 JP2016520520 A5 JP 2016520520A5 JP 2016502189 A JP2016502189 A JP 2016502189A JP 2016502189 A JP2016502189 A JP 2016502189A JP 2016520520 A5 JP2016520520 A5 JP 2016520520A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antibody
notch2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502189A
Other languages
English (en)
Japanese (ja)
Other versions
JP6527132B2 (ja
JP2016520520A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026588 external-priority patent/WO2014151866A1/en
Publication of JP2016520520A publication Critical patent/JP2016520520A/ja
Publication of JP2016520520A5 publication Critical patent/JP2016520520A5/ja
Application granted granted Critical
Publication of JP6527132B2 publication Critical patent/JP6527132B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502189A 2013-03-15 2014-03-13 肝臓がんの診断及び治療のための組成物及び方法 Expired - Fee Related JP6527132B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789475P 2013-03-15 2013-03-15
US61/789,475 2013-03-15
PCT/US2014/026588 WO2014151866A1 (en) 2013-03-15 2014-03-13 Compositions and methods for diagnosis and treatment of hepatic cancers

Publications (3)

Publication Number Publication Date
JP2016520520A JP2016520520A (ja) 2016-07-14
JP2016520520A5 true JP2016520520A5 (enExample) 2017-03-23
JP6527132B2 JP6527132B2 (ja) 2019-06-05

Family

ID=50483571

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502189A Expired - Fee Related JP6527132B2 (ja) 2013-03-15 2014-03-13 肝臓がんの診断及び治療のための組成物及び方法

Country Status (20)

Country Link
US (3) US9550829B2 (enExample)
EP (1) EP2970476A1 (enExample)
JP (1) JP6527132B2 (enExample)
KR (1) KR20150128707A (enExample)
CN (1) CN105143264A (enExample)
AU (1) AU2014236815B2 (enExample)
BR (1) BR112015020290A2 (enExample)
CA (1) CA2902765A1 (enExample)
CL (1) CL2015002571A1 (enExample)
CR (1) CR20150483A (enExample)
EA (1) EA201591705A1 (enExample)
HK (1) HK1211963A1 (enExample)
IL (1) IL240116A0 (enExample)
MA (1) MA38495A1 (enExample)
MX (1) MX2015011444A (enExample)
PE (1) PE20151750A1 (enExample)
PH (1) PH12015501997A1 (enExample)
SG (2) SG11201507427QA (enExample)
TW (1) TW201511770A (enExample)
WO (1) WO2014151866A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9663573B2 (en) 2011-10-05 2017-05-30 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
BR112015003032B1 (pt) 2012-08-13 2023-03-28 Genentech, Inc Anticorpos isolados, imunoconjugado, formulação farmacêutica e uso do anticorpo
WO2014141064A1 (en) 2013-03-13 2014-09-18 Novartis Ag Notch2 binding molecules for treating respiratory diseases
US9550829B2 (en) 2013-03-15 2017-01-24 Genentech, Inc. Compositions and methods for diagnosis and treatment of hepatic cancers
WO2015123325A1 (en) 2014-02-12 2015-08-20 Genentech, Inc. Anti-jagged1 antibodies and methods of use
AR105757A1 (es) * 2015-03-06 2017-11-08 Sorrento Therapeutics Inc Anticuerpos anti-jag1 como agentes terapéuticos
CN104990905B (zh) * 2015-06-30 2017-12-29 曲凯 一种基于固相酶联免疫荧光斑点的肝癌转移诊断试剂盒
US11026996B2 (en) * 2016-05-25 2021-06-08 The Trustees Of Columbia University In The City Of New York Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
CN106053812B (zh) * 2016-06-29 2017-12-08 厦门生迪生物技术有限公司 一种用于肝癌早期筛查和诊断的多种自身抗体联合检测elisa试剂盒
JOP20190259A1 (ar) * 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
CN108187050A (zh) * 2018-01-18 2018-06-22 石河子大学 抑制食管癌细胞增殖的药物
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
KR20210044251A (ko) 2018-08-13 2021-04-22 베이징 페르칸스 온콜로지 컴퍼니 리미티드 암 치료용 바이오마커
KR102325972B1 (ko) * 2020-05-06 2021-11-16 아주대학교산학협력단 간암 치료 반응 예측용 spp1 바이오마커 및 이의 용도
WO2022061595A1 (en) * 2020-09-23 2022-03-31 Xiang Li Notch1 biomarkers for cancer therapy
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US6004924A (en) 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
WO2001044463A1 (en) 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
EP1242438B1 (en) 1999-12-29 2006-11-08 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス,インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Gdp−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド 合成抗体ファージライブラリー
US20040101847A1 (en) 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch2 expression
EP1531825A2 (en) 2002-08-29 2005-05-25 University Of Southampton Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CN1942483B (zh) 2004-04-13 2012-09-26 弗·哈夫曼-拉罗切有限公司 抗p型选凝素抗体
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AT502055B1 (de) 2005-06-21 2007-11-15 Univ Wien Med Anti tumor medikament
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20080241150A1 (en) 2006-05-15 2008-10-02 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
EP2059533B1 (en) 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008140826A1 (en) 2007-05-15 2008-11-20 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
WO2009124931A2 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
EP2307051B1 (en) * 2008-07-08 2015-02-11 OncoMed Pharmaceuticals, Inc. Notch-binding agents and antagonists and methods of use thereof
EP2344536A1 (en) 2008-09-19 2011-07-20 MedImmune, LLC Antibodies directed to dll4 and uses thereof
AU2009298569A1 (en) 2008-10-01 2010-04-08 Genentech, Inc. Anti-Notch2 antibodies and methods of use
US8945569B2 (en) * 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
US9663573B2 (en) 2011-10-05 2017-05-30 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
WO2013192550A2 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
BR112015003032B1 (pt) 2012-08-13 2023-03-28 Genentech, Inc Anticorpos isolados, imunoconjugado, formulação farmacêutica e uso do anticorpo
US9550829B2 (en) 2013-03-15 2017-01-24 Genentech, Inc. Compositions and methods for diagnosis and treatment of hepatic cancers
WO2015123325A1 (en) 2014-02-12 2015-08-20 Genentech, Inc. Anti-jagged1 antibodies and methods of use

Similar Documents

Publication Publication Date Title
JP2016520520A5 (enExample)
JP6942465B2 (ja) 抗pdl1抗体製剤
JP2020099324A5 (enExample)
JP2014158469A5 (enExample)
US20220372160A1 (en) Anti-CD39 Antibody Compositions and Methods
JP2013531655A5 (enExample)
JP2016020389A5 (enExample)
JP2017530691A5 (enExample)
RU2012137515A (ru) Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
HRP20180352T1 (hr) Protutijela anti-fcrh5
JP2016509582A5 (enExample)
RU2012136113A (ru) Ингибирование axl сигнализации в антиметастатической терапии
JP2014511179A5 (enExample)
TW201406391A (zh) 抗-il-23抗體
JP2017526339A5 (enExample)
CN103562403A (zh) 识别肿瘤起始细胞的抗体和抗原及其应用
JP2018529635A5 (enExample)
TW201511770A (zh) 診斷及治療肝癌之組合物及方法
JP2011518773A5 (enExample)
JP2016509585A5 (enExample)
JP2017538439A5 (enExample)
RU2017145662A (ru) Моноклональные антитела и способы их применения
Xia et al. Preparation and characterization of anti-GPC3 nanobody against hepatocellular carcinoma
CN104853774B (zh) Il-20拮抗剂用于治疗肝脏疾病
TW201809282A (zh) 用於診斷及在免疫療法中使用之基質基因印記